Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

THIS YEAR the Spanish capital, Madrid, provided the backdrop for Europe’s biggest urological event, the 40th Annual European ...

In a previous interview with Urology Times®, Li described the trial: “In the MoonRISe-1 study, we're studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 ...

Asked about the take-home message of the study, Xu said, “I think the take-home message for the practicing urologist would really be just to know that programs such as the Mark Cuban Cost Plus Drug ...